CRISM Therapeutics Corporation develops a drug delivery technology for the clinical performance of cancer treatments for solid tumors through the local delivery of chemotherapy drugs in the British Virgin Islands. The company's lead product is ChemoSeed, which can be implanted directly into the tumour or the resection margin following the removal of a tumour. It also provides formulation and consultancy services. The company was formerly known as Amur Minerals Corporation and changed its name to CRISM Therapeutics Corporation in May 2024. CRISM Therapeutics Corporation is based in Road Town, the British Virgin Islands.…
Crism Therapeutics Treats First Patient in Mid-stage Glioblastoma Trial
CRISM Therapeutics (LON: CRTX) is listed on the London Stock Exchange, where its shares trade in pence sterling (GBp). It belongs to the Biotechnology industry, part of the Healthcare sector.
The shares were at 8.000 GBp on 20 November 2026, down 33.3% over 52 weeks. Its 52-week range is 7.650 GBp to 18.50 GBp: the price is 56.8% below the high and 4.6% above the low.
Its market capitalisation is 6.37M GBP.
CRISM Therapeutics reports return on equity of -134.4%.
It holds more cash than debt, a net cash position of 2.27M GBP. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.
No upcoming events tracked.